RenovoRx Inc.

0.97
-0.01 (-1.02%)
At close: Apr 24, 2025, 12:14 PM

Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.

Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx Inc.
RenovoRx Inc. logo
Country United States
IPO Date Aug 26, 2021
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Shaun R. Bagai

Contact Details

Address:
4546 El Camino Real
Los Altos, California
United States
Website https://renovorx.com

Stock Details

Ticker Symbol RNXT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574094
CUSIP Number 75989R107
ISIN Number US75989R1077
Employer ID 27-1448452
SIC Code 2834

Key Executives

Name Position
Shaun R. Bagai Chief Executive Officer, Secretary & Director
Dr. Ramtin Agah M.D. Founder, Chairman of Board & Chief Medical Officer
Leesa Gentry Chief Clinical Officer
Robert Strasser Vice President of Operations and R&D
Ronald B. Kocak CPA, CGMA Vice President, Controller & Principal Accounting Officer
Ryan Witt Senior Vice President and Head of Corporate Strategy & Partnerships

Latest SEC Filings

Date Type Title
Apr 17, 2025 4 Filing
Apr 16, 2025 4 Filing
Apr 16, 2025 4 Filing
Apr 16, 2025 4 Filing
Apr 16, 2025 4 Filing
Apr 16, 2025 4 Filing
Apr 14, 2025 4 Filing
Apr 10, 2025 4 Filing
Apr 10, 2025 4 Filing
Apr 10, 2025 4 Filing